EE03271B1 - Inimesele kohandatud antikehad või nende siduvad proteiinid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon - Google Patents

Inimesele kohandatud antikehad või nende siduvad proteiinid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon

Info

Publication number
EE03271B1
EE03271B1 EE9600108A EE9600108A EE03271B1 EE 03271 B1 EE03271 B1 EE 03271B1 EE 9600108 A EE9600108 A EE 9600108A EE 9600108 A EE9600108 A EE 9600108A EE 03271 B1 EE03271 B1 EE 03271B1
Authority
EE
Estonia
Prior art keywords
preparation
methods
pharmaceutical composition
composition containing
binding proteins
Prior art date
Application number
EE9600108A
Other languages
English (en)
Estonian (et)
Inventor
Yee-Tharn Lin Augustine
Original Assignee
T Cell Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences, Inc. filed Critical T Cell Sciences, Inc.
Publication of EE03271B1 publication Critical patent/EE03271B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EE9600108A 1993-12-08 1994-11-21 Inimesele kohandatud antikehad või nende siduvad proteiinid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon EE03271B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325182A GB9325182D0 (en) 1993-12-08 1993-12-08 Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
PCT/IB1994/000387 WO1995016038A2 (en) 1993-12-08 1994-11-21 Humanized antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EE03271B1 true EE03271B1 (et) 2000-06-15

Family

ID=10746330

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600108A EE03271B1 (et) 1993-12-08 1994-11-21 Inimesele kohandatud antikehad või nende siduvad proteiinid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon

Country Status (24)

Country Link
US (1) US5861155A (ru)
EP (1) EP0737250A1 (ru)
JP (1) JPH09509307A (ru)
KR (2) KR100239607B1 (ru)
CN (1) CN1063792C (ru)
AU (1) AU699249B2 (ru)
BR (1) BR9408278A (ru)
CA (1) CA2178622A1 (ru)
CZ (2) CZ287347B6 (ru)
EE (1) EE03271B1 (ru)
FI (1) FI962377A (ru)
GB (1) GB9325182D0 (ru)
HU (1) HUT75553A (ru)
IL (1) IL111926A (ru)
LV (1) LV11631B (ru)
NO (1) NO962346L (ru)
NZ (1) NZ276170A (ru)
PL (1) PL180157B1 (ru)
RU (1) RU2139934C1 (ru)
SG (1) SG48420A1 (ru)
SK (1) SK73596A3 (ru)
UA (1) UA29494C2 (ru)
WO (1) WO1995016038A2 (ru)
ZA (1) ZA949341B (ru)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CN1064052C (zh) * 1997-09-29 2001-04-04 中国科学院微生物研究所 甲状旁腺素相关蛋白人源化抗体及其制备方法
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
GB9906233D0 (en) * 1999-03-19 1999-05-12 Univ Newcastle Bone formation
EP1326991A2 (en) * 2000-10-20 2003-07-16 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
AU2003221118A1 (en) * 2002-03-22 2003-10-08 Bipha Corporation Immunoglobulin/hydrophilic peptide complexes
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
GB0302740D0 (en) * 2003-02-06 2003-03-12 Axis Shield Asa Assay
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
PT1742966E (pt) * 2004-04-22 2014-02-05 Agensys Inc Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1
EP1921137A4 (en) * 2005-06-21 2011-01-26 Med & Biological Lab Co Ltd ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
KR100740201B1 (ko) * 2005-10-21 2007-07-18 삼성전자주식회사 듀얼 전송 스트림 생성 장치 및 그 방법
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
CA2650459A1 (en) * 2006-04-28 2007-11-08 Eth Zuerich Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
PL2087002T3 (pl) * 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
JP5732182B2 (ja) * 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
US8604172B2 (en) * 2009-04-17 2013-12-10 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8158124B2 (en) * 2007-05-30 2012-04-17 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
JP2010535503A (ja) 2007-08-10 2010-11-25 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ（エー＊エスティーエーアール） 癌の診断および治療のためのｖｈｚ
US7867497B2 (en) * 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
JP5756014B2 (ja) * 2008-08-08 2015-07-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） がんの診断および治療のためのｖｈｚ
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
JP2012511026A (ja) * 2008-12-05 2012-05-17 エルパス・インコーポレイテッド 抗脂抗体結晶構造を用いた抗体設計
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100292443A1 (en) * 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
HUE037992T2 (hu) 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
EP3623381A1 (en) 2011-05-19 2020-03-18 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
DK2739310T3 (en) 2011-08-05 2018-07-16 Res Found Dev Improved methods and compositions for modulating OLFML3-mediated angiogenesis
AU2013308409A1 (en) 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
CN114621346A (zh) 2013-08-21 2022-06-14 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR102418372B1 (ko) 2016-03-29 2022-07-08 주식회사 에스티큐브 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN117050176A (zh) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
WO2020092969A1 (en) 2018-11-02 2020-05-07 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
WO2020172601A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114126714A (zh) * 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
EP4139363A4 (en) 2020-04-24 2024-09-04 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES BINDING TO T-CELL ASSOCIATED CANCER CELLS AND USES THEREOF
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
JP2023551535A (ja) 2020-12-01 2023-12-08 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｔ細胞がんを治療するための方法および材料
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
NZ234586A (en) * 1989-07-19 1993-02-25 Arthur Allen Vandenbark Peptide of a t-cell receptor capable of inducing protection from immune-related disease
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5067193A (en) * 1990-07-26 1991-11-26 Container Graphics Corporation Rotary printing plate washing apparatus
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
PL180157B1 (en) 2000-12-29
KR960706560A (ko) 1996-12-09
SK73596A3 (en) 1997-05-07
FI962377A0 (fi) 1996-06-07
PL314908A1 (en) 1996-09-30
ZA949341B (en) 1996-05-24
UA29494C2 (ru) 2000-11-15
GB9325182D0 (en) 1994-02-09
WO1995016038A2 (en) 1995-06-15
CA2178622A1 (en) 1995-06-15
LV11631A (lv) 1996-12-20
LV11631B (en) 1997-04-20
IL111926A0 (en) 1995-03-15
HU9601574D0 (en) 1996-07-29
KR100258902B1 (en) 2000-06-15
CN1142855A (zh) 1997-02-12
HUT75553A (en) 1997-05-28
CN1063792C (zh) 2001-03-28
CZ162896A3 (en) 1997-01-15
RU2139934C1 (ru) 1999-10-20
CZ287298B6 (cs) 2000-10-11
EP0737250A1 (en) 1996-10-16
IL111926A (en) 2002-07-25
SG48420A1 (en) 1998-04-17
JPH09509307A (ja) 1997-09-22
FI962377A (fi) 1996-07-30
CZ287347B6 (en) 2000-10-11
US5861155A (en) 1999-01-19
NO962346D0 (no) 1996-06-05
AU699249B2 (en) 1998-11-26
NZ276170A (en) 1998-05-27
NO962346L (no) 1996-08-06
AU1033395A (en) 1995-06-27
WO1995016038A3 (en) 1995-07-06
KR100239607B1 (ko) 2000-01-15
BR9408278A (pt) 1996-12-17

Similar Documents

Publication Publication Date Title
EE03271B1 (et) Inimesele kohandatud antikehad või nende siduvad proteiinid, nende valmistamismeetodid ja neid sisaldav farmatseutiline kompositsioon
FI943565A (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
EE9900115A (et) Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO922155L (no) Peptider og antistoffer som inhiberer integrinligandbinding
NO992779D0 (no) OB-fusjonsproteinpreparater og fremgangsmÕte for fremstilling av slike
EE9400455A (et) Peptiidi derivaadid, nende valmistamise protsess, neid sisaldavad ravimpreparaadid ja nende kasutamine
DK560784A (da) Hoejrenset protein, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende det
AU2573595A (en) Antibodies which bind to insect gut proteins and their use
EE03111B1 (et) Glükokortikosteroidi epimeerid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
AU7095887A (en) Human gamma interferon-specific receptor protein, antibody against said protein and said antibody and compositions containing said protein and antibody
EE9700333A (et) Substitueeritud 4-fenüülaminotiasoolid, nende valmistamise meetod ja neid sisaldavad farmakoloogilised kompositsioonid
FI962844A0 (fi) T-soluantigeenireseptorin V-alueen proteiineja ja menetelmiä niiden valmistamiseksi
EE03929B1 (et) Sünteetilised polüsahhariidid, nende valmistamisemeetod ja neid sisaldavad farmatseutilised kompositsioonid
DK556689D0 (da) Antistof-konjugater, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende disse
FI961938A0 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE03611B1 (et) Taksoidid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
FI956278A (fi) Substituoituja 4-fenyylitiatsolijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DK102990A (da) Thieno-triazolodiazepinderivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
NO915017D0 (no) Monoklonale antistoffer og fremgangsmaate for deres fremstilling
BR9709406B1 (pt) fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas.
FI955123A (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi